Selected Grants
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer (KLK2-PASenger, 78278343PCR3003)
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2026 - 2030A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2024 - 2029TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in c
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2029Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site Award
ResearchCo Investigator · Awarded by Department of Defense · 2024 - 2028External Relationships
- AstraZeneca
- Bayer
- Merck Sharpe & Dohme (Merck & Co, USA)
- Novartis pharmaceuticals
- Pfizer Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.